Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02695290
Title Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications

lung non-small cell carcinoma

Therapies

Afatinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.